Does Epigenetic Therapy With Panobinostat Reduce CRPC Bicalutamide Resistance?

Panobinostat plus bicalutamide increased radiographic progression-free survival in patients with CRPC resistant to second-line antiandrogen therapy.

from Latest articles from Cancer Therapy Advisor Male Reproductive Cancers https://ift.tt/2SFAxvv